{"id":1773490,"date":"2022-12-13T07:58:28","date_gmt":"2022-12-13T12:58:28","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=1773490"},"modified":"2022-12-13T10:05:19","modified_gmt":"2022-12-13T15:05:19","slug":"fda-says-ivermectin-doesnt-work-against-covid-19-but-points-to-studies-that-show-it-does-2","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/fda-says-ivermectin-doesnt-work-against-covid-19-but-points-to-studies-that-show-it-does-2\/","title":{"rendered":"FDA Says Ivermectin Doesn\u2019t Work Against COVID-19 but Points to Studies That Show It Does"},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"float:left\"><div class=\"counts mashsbcount\">30<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Ffda-says-ivermectin-doesnt-work-against-covid-19-but-points-to-studies-that-show-it-does-2%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=1773490&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><p>The U.S. <a href=\"https:\/\/www.theepochtimes.com\/t-food-and-drug-administration\">Food and Drug Administration<\/a> (<a href=\"https:\/\/www.theepochtimes.com\/t-fda\">FDA<\/a>) says a drug called ivermectin does not work against <a href=\"https:\/\/www.theepochtimes.com\/t-covid-19\">COVID-19<\/a> but links to studies that show it does, an Epoch Times review has found.<\/p>\n<p>The FDA\u2019s website states, \u201cCurrently available data do not show ivermectin is effective against COVID-19.\u201d<\/p>\n<p>But half of <a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=COVID-19&#038;term=ivermectin&#038;cntry=&#038;state=&#038;city=&#038;dist=&#038;Search=Search\">the studies<\/a> to which the FDA <a href=\"https:\/\/www.fda.gov\/consumers\/consumer-updates\/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19\">points<\/a>\u00a0support using ivermectin against COVID-19, according to the review.<\/p>\n<p>The papers cut against the drug agency\u2019s repeated exhortations for people not to take ivermectin for COVID-19. In Twitter posts, public statements, and emails, FDA officials have repeatedly warned against ivermectin. Some of those statements <a href=\"https:\/\/www.theepochtimes.com\/fda-says-telling-people-not-to-take-ivermectin-for-covid-19-was-just-a-recommendation_4873897.html\">triggered a lawsuit<\/a> from doctors who say the agency\u2019s role is to approve drugs, not to issue recommendations. The suit <a href=\"https:\/\/www.theepochtimes.com\/lawsuit-against-fda-over-ivermectin-dismissed-by-judge_4906931.html\">was dismissed this week<\/a>.<\/p>\n<p>Dr. Pierre Kory, who frequently prescribes ivermectin for COVID-19 and co-authored <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8088823\/\">a meta-analysis<\/a> that concluded the drug is effective against the illness, told The Epoch Times that the government\u2019s position on ivermectin \u201cis one of the most glaring examples of the corruption of modern evidence based medicine.\u201d<\/p>\n<p>\u201cThere\u2019s one message they want everyone to understand. And that message is that ivermectin doesn\u2019t work,\u201d Kory said. \u201cThat\u2019s not a scientific conclusion, that\u2019s theirs. That\u2019s their perverted and distorted interpretation of the data.\u201d<\/p>\n<p>The FDA\u2019s media office did not respond to a request for comment.<\/p>\n<p>Dr. Janet Woodcock, a top official at the agency who was its commissioner\u00a0from January 2021 to February 2022, told The Epoch Times via email that \u201civermectin has been shown to be ineffective against COVID in large randomized trials.\u201d<\/p>\n<figure id=\"attachment_4908192\" class=\"wp-caption alignnone\"><a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-content\/uploads\/2022\/12\/fda-sign-1200x800-1.jpg\" rel=\"attachment wp-att-4908192\"><img loading=\"lazy\" decoding=\"async\" class=\"lazy size-large wp-image-4908192\" src=\"https:\/\/www.theepochtimes.com\/assets\/themes\/eet\/images\/white.png\" data-src=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-content\/uploads\/2022\/12\/fda-sign-1200x800-1.jpg\" alt=\"Epoch Times Photo\" width=\"640\" height=\"427\"   style=\"display:none\"><figcaption class=\"wp-caption-text\"><noscript><img loading=\"lazy\" decoding=\"async\" class=\"size-large wp-image-4908192\" src=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-content\/uploads\/2022\/12\/fda-sign-1200x800-1.jpg\" alt=\"Epoch Times Photo\" width=\"640\" height=\"427\" \/><\/noscript><\/figcaption><\/a> A sign for the Food And Drug Administration outside its headquarters in White Oak, Md., on July 20, 2020. (Sarah Silbiger\/Getty Images)<\/figure>\n<h2>Studies<\/h2>\n<p>The FDA\u2019s website points to a U.S. National Library of Medicine database of studies analyzing ivermectin against COVID-19. There are 88 studies listed in the database.<\/p>\n<p>Out of studies\u00a0that are listed, have been completed, and have results reported, half show or indicate ivermectin effectively combats or prevents COVID-19, according to the review by The Epoch Times.<\/p>\n<p>They include papers reporting on results from randomized, controlled trials, which are often offered as the highest level of evidence by U.S. government officials. Such trials feature\u00a0a group that receives a placebo and a group that receives the drug, randomization into groups,\u00a0and blinding, or shielding operators and\/or patients from the knowledge of which participants are receiving ivermectin.<\/p>\n<p>Among the papers is a randomized, blinded, controlled trial that found people who received ivermectin and doxycycline, an antibiotic, recovered faster from COVID-19 than those who received a placebo.<\/p>\n<p>Bangladeshi researchers reported the results from the trial of 363 participants on May 13, 2021, in the <a href=\"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605211013550?url_ver=Z39.88-2003&#038;rfr_id=ori:rid:crossref.org&#038;rfr_dat=cr_pub%20%200pubmed\">Journal of International Medical Research<\/a>.<\/p>\n<p>\u201cPatients with mild-to-moderate COVID-19 infection treated with ivermectin plus doxycycline recovered earlier, were less likely to progress to more serious disease, and were more likely to be COVID-19 negative by RT-PCR on day 14,\u201d they said. PCR has been used to test for COVID-19.<\/p>\n<p>Another paper, published on July 7, 2022, in the <a href=\"https:\/\/www.ijidonline.com\/article\/S1201-9712(22)00399-X\/fulltext#%20\">International Journal of Infectious Diseases<\/a>, found that that ivermectin decreased the level of COVID-19 and its viability. Israeli researchers in the randomized, controlled, open label trial compared 47 patients who received ivermectin against 42 who received placebos and said that \u201civermectin significantly reduced the time of viral shedding and affected viral viability when initiated in the first week after evidence of infection.\u201d<\/p>\n<p>\u201cThere were lower viral loads and less viable cultures in the ivermectin group, which shows its anti-SARS-CoV-2 activity,\u201d the researchers said. SARS-CoV-2 is a name for the virus that causes COVID-19.<\/p>\n<p>A third paper concluded that a regimen of ivermectin and carrageenan works as a prophylaxis, or preventative medicine.\u00a0Argentinian researchers found in the\u00a0observational trial involving\u00a0229 health care workers that ivermectin helped prevent COVID-19 infection. A followup study involving nearly 1,200 workers confirmed the results. Both sets were reported in the\u00a0<a href=\"https:\/\/medicalpressopenaccess.com\/single_article.php?refid=82\">Journal of Clinical and Biomedical Investigation<\/a> on Nov. 17, 2020.<\/p>\n<p><a href=\"https:\/\/www.theepochtimes.com\/t-ivermectin\">Ivermectin<\/a> \u201ccould have saved so many lives,\u201d\u00a0H\u00e9ctor Carvallo, one of the researchers, told The Epoch Times via email, adding that \u201cit\u2019s been a crime against mankind to prevent its prescription.\u201d<\/p>\n<p>Some other studies, including the largest ones, either found indications that ivermectin works against COVID-19 but did not achieve statistical significance or found no evidence that ivermectin is effective.<\/p>\n<p>That includes a randomized, controlled, double-blind <a href=\"https:\/\/www.mdpi.com\/2036-7449\/14\/2\/20\">2021 study<\/a> by Mexican researchers that found ivermectin did not significantly impact hospitalization duration or mortality, and a randomized, controlled, double-blind <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2201662\">2022 trial<\/a> by U.S. researchers that concluded ivermectin did not prevent hypoxemia, hospitalization, or death.<\/p>\n<h2>FDA Intervention<\/h2>\n<p>Scientists in Australia in April 2020 found that ivermectin worked well against the COVID-19 virus <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0166354220302011?via%3Dihub\">in cell culture<\/a>, prompting doctors in multiple countries, including Peru and the United States, to start using it against the new illness.<\/p>\n<p>Ivermectin is approved by the FDA to treat parasites. One version is used on horses and other animals.<\/p>\n<p>The FDA <a href=\"https:\/\/www.fda.gov\/animal-veterinary\/product-safety-information\/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans\">quickly warned<\/a> against using the animal form and said that people should \u201cnot take any form of ivermectin unless it has been prescribed to them by a licensed health care provider and is obtained through a legitimate source.\u201d<\/p>\n<p>Studies later in the year suggested ivermectin worked well in humans who had COVID-19, including halting the progression of disease (<a href=\"https:\/\/www.medrxiv.org\/content\/10.1101\/2020.09.10.20191619v1.full.pdf\">pdf<\/a>), <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2052297521000792\">helping patients improve faster<\/a>, and <a href=\"https:\/\/ejmed.org\/index.php\/ejmed\/article\/view\/599\">preventing COVID-19 infection<\/a>, though other studies returned results that did not support ivermectin as a treatment.<\/p>\n<p>The FDA maintained its stance against COVID-19, and created a new web page on March 5, 2021. It <a href=\"https:\/\/archive.ph\/DUKMj#selection-1305.0-1305.157\">initially said<\/a>, \u201cThe FDA has not reviewed data to support use of ivermectin in COVID-19 patients to treat or to prevent COVID-19; however, some initial research is underway.\u201d<\/p>\n<p>In August 2021, the FDA urged people against using ivermectin by <a href=\"https:\/\/www.theepochtimes.com\/fda-was-excited-by-response-to-edgy-ivermectin-twitter-post-documents-show_4884257.html\">telling them<\/a> that \u201cyou are not a horse.\u201d It linked to the page, which was updated the following month with the language it now contains about data not showing ivermectin is effective.<\/p>\n<p>American doctors are allowed to prescribe drugs approved for one use for a different use, a practice known as off-label. But doctors who prescribed ivermectin soon found that many pharmacies stopped filling prescriptions, citing advice from the FDA and other U.S. government bodies.<\/p>\n<table style=\"width: 785px;\">\n<thead>\n<tr>\n<td><strong>Studies on Ivermectin Against COVID-19<\/strong><\/td>\n<td><strong>Date<\/strong><\/td>\n<td><strong>Journal<\/strong><\/td>\n<td><strong>Participants<\/strong><\/td>\n<td><strong>Outcome<\/strong><\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><a href=\"https:\/\/www.alliedacademies.org\/articles\/effects-of-ivermectinazithromycincholecalciferol-combined-therapy-on-covid19-infected-patients-a-proof-of-concept-study.pdf\">Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study<\/a><\/td>\n<td>2020<\/td>\n<td>Biomedical Research<\/td>\n<td>35<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.medrxiv.org\/content\/10.1101\/2020.07.07.20145979v1.full.pdf\">Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management<\/a><\/td>\n<td>July 8, 2020<\/td>\n<td>Preprint<\/td>\n<td>87<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.medrxiv.org\/content\/10.1101\/2020.09.10.20191619v1.full.pdf\">Safety and Efficacy of the Combined Use of Ivermectin, Dexamethasone, Enoxaparin and Aspirin Against COVID-19<\/a><\/td>\n<td>Sept. 15, 2020<\/td>\n<td>Preprint<\/td>\n<td>167<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/medicalpressopenaccess.com\/single_article.php?refid=82\">Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel<\/a><\/td>\n<td>Nov. 17, 2020<\/td>\n<td>Journal of Biomedical Research and Clinical Investigation<\/td>\n<td>229<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.jcdr.net\/articles\/PDF\/14529\/46795_CE[Ra]_F(Sh)_PF1(SY_OM)_PFA_(OM)_PN(KM).pdf\">Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial<\/a><\/td>\n<td>Feb. 1, 2021<\/td>\n<td>Journal of Clinical and Diagnostic Research<\/td>\n<td>203 contacts to 52 index cases<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.medrxiv.org\/content\/10.1101\/2021.02.02.21250840v1.full.pdf\">Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease<\/a><\/td>\n<td>Feb. 5, 2021<\/td>\n<td>Preprint<\/td>\n<td>86<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.ejmo.org\/10.14744\/ejmo.2021.16263\/pdf\/\">A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patient<\/a>s<\/td>\n<td>Feb. 25, 2021<\/td>\n<td>Eurasian Journal of Medicine and Oncology<\/td>\n<td>116<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605211013550?url_ver=Z39.88-2003&#038;rfr_id=ori:rid:crossref.org&#038;rfr_dat=cr_pub%20%200pubmed\">Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial<\/a><\/td>\n<td>May 2021<\/td>\n<td>International Journal of International Medical Research<\/td>\n<td>363<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8014583\/\">Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID\u201019<\/a><\/td>\n<td>May 2021<\/td>\n<td>Journal of Medical Virology<\/td>\n<td>113<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.iraqijms.net\/upload\/pdf\/iraqijms60db8b76d3b1e.pdf\">Controlled Randomized Clinical Trial on Using Ivermectin with Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq<\/a><\/td>\n<td>May 6, 2021<\/td>\n<td>Iraqi Journal of Medical Sciences<\/td>\n<td>140<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.dovepress.com\/clinical-biochemical-and-molecular-evaluations-of-ivermectin-mucoadhes-peer-reviewed-fulltext-article-IJN\">Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19<\/a><\/td>\n<td>June 15, 2021<\/td>\n<td>International Journal of Nanomedicine<\/td>\n<td>114<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.cureus.com\/articles\/63131-ivermectin-as-a-sars-cov-2-pre-exposure-prophylaxis-method-in-healthcare-workers-a-propensity-score-matched-retrospective-cohort-study\">Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study<\/a><\/td>\n<td>Aug. 13, 2021<\/td>\n<td>Cureus<\/td>\n<td>271<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8415509\/\">Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina<\/a><\/td>\n<td>Sept-Oct, 2021<\/td>\n<td>American Journal of Therapeutics<\/td>\n<td>234<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.futuremedicine.com\/doi\/full\/10.2217\/fmb-2022-0014?rfr_dat=cr_pub++0pubmed&#038;url_ver=Z39.88-2003&#038;rfr_id=ori%3Arid%3Acrossref.org\">Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients<\/a><\/td>\n<td>Feb. 9, 2022<\/td>\n<td>Future Microbiology<\/td>\n<td>24<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/rsdjournal.org\/index.php\/rsd\/article\/view\/30844\/26582\">Randomized trials \u2013 Ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers<\/a><\/td>\n<td>June 21, 2022<\/td>\n<td>Research, Society and Development<\/td>\n<td>254<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.ijidonline.com\/article\/S1201-9712(22)00399-X\/fulltext\">The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 \u2013 a double-blind, randomized placebo-controlled trial<\/a><\/td>\n<td>July 7, 2022<\/td>\n<td>International Journal of Infectious Diseases<\/td>\n<td>89<\/td>\n<td>Positive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(20)30464-8\/fulltext\">The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial<\/a><\/td>\n<td>Feb. 1, 2021<\/td>\n<td>The Lancet<\/td>\n<td>24<\/td>\n<td>Mixed<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.ijidonline.com\/article\/S1201-9712(21)00345-3\/pdf\">Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial<\/a><\/td>\n<td>April 2021<\/td>\n<td>International Journal of Infectious Diseases<\/td>\n<td>3037<\/td>\n<td>Mixed<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.27122\">Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study<\/a><\/td>\n<td>June 2, 2021<\/td>\n<td>Journal of Medical Virology<\/td>\n<td>164<\/td>\n<td>Mixed<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(21)00239-X\/fulltext\">Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial<\/a><\/td>\n<td>July 1, 2021<\/td>\n<td>The Lancet<\/td>\n<td>45<\/td>\n<td>Mixed<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/assets.researchsquare.com\/files\/rs-1640339\/v1\/d543ffee-d91f-4eda-a813-77d3db899e2b.pdf?c=1653318211\">Ivermectin compared with placebo in the clinical evolution of Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial<\/a><\/td>\n<td>May 23, 2022<\/td>\n<td>Preprint<\/td>\n<td>66<\/td>\n<td>Mixed<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06649-3\/\">Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial<\/a><\/td>\n<td>Aug. 26, 2022<\/td>\n<td>Trials<\/td>\n<td>72<\/td>\n<td>Mixed<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.mdpi.com\/2036-7449\/14\/2\/20\">Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial<\/a><\/td>\n<td>Feb. 23, 2021<\/td>\n<td>Infectious Disease Reports<\/td>\n<td>106<\/td>\n<td>Not Supportive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2777389\">Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19<\/a><\/td>\n<td>March 4, 2021<\/td>\n<td>Journal of American Medical Association<\/td>\n<td>476<\/td>\n<td>Not Supportive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06104-9\">Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients<\/a><\/td>\n<td>May 4, 2021<\/td>\n<td>BMC Infectious Diseases<\/td>\n<td>66<\/td>\n<td>Not Supportive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06348-5\">Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial<\/a><\/td>\n<td>July 2, 2021<\/td>\n<td>BMC Infectious Diseases<\/td>\n<td>501<\/td>\n<td>Not Supportive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2789362\">Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities<\/a><\/td>\n<td>Feb. 18, 2022<\/td>\n<td>Journal of American Medical Association<\/td>\n<td>490<\/td>\n<td>Not Supportive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/11101849.2022.2089518\">Effect of combined use of ivermectin and colchicine in COVID-19 patients<\/a><\/td>\n<td>June 22, 2022<\/td>\n<td>Egyptian Journal of\u00a0Anesthesia<\/td>\n<td>135<\/td>\n<td>Not Supportive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.medrxiv.org\/content\/10.1101\/2022.07.15.22277570v1.full.pdf\">Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19<\/a><\/td>\n<td>July 19, 2022<\/td>\n<td>Preprint<\/td>\n<td>96<\/td>\n<td>Not Supportive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2201662\">Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19<\/a><\/td>\n<td>Aug. 18, 2022<\/td>\n<td>New England Journal of Medicine<\/td>\n<td>1323<\/td>\n<td>Not Supportive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/14787210.2022.2098113?journalCode=ierz20\">Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial<\/a><\/td>\n<td>Oct 20, 2022<\/td>\n<td>Expert Review of Anti-infective Therapy<\/td>\n<td>unclear<\/td>\n<td>Not Supportive<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2797483\">Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19<\/a><\/td>\n<td>Oct. 25, 2022<\/td>\n<td>Journal of American Medical Association<\/td>\n<td>1591<\/td>\n<td>Not Supportive<\/td>\n<\/tr>\n<tr>\n<td><em>Note: Only studies from the database linked to by the FDA that have been completed and have had results released are included<\/em><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><\/h2>\n<h2>Half of Studies Supportive<\/h2>\n<p>The FDA does not cite studies on its website to support its statement that data \u201cdo not show ivermectin is effective against COVID-19.\u201d<\/p>\n<p>\u201cClinical trials assessing ivermectin tablets for the prevention or treatment of COVID-19 in people are ongoing,\u201d the agency adds, providing a link to the\u00a0U.S. National Library of Medicine\u2019s database.<\/p>\n<p>Of the 88 studies listed there, 56 fall under one of three categories: have not been completed, were completed but results have not been reported, or were completed and have since been retracted or otherwise withdrawn.<\/p>\n<p>Of the remaining 32, 16 found or indicate ivermectin is effective as a COVID-19 treatment or\u00a0prophylactic, according to the Epoch Times review.<\/p>\n<p>Two of the trials were randomized, controlled, and blinded. Nine others were randomized and controlled but were not blinded at all.\u00a0Most of the rest were observational, meaning they analyzed data from real-world settings like hospitals, or used observational data to create what\u2019s known as a synthetic control group.<\/p>\n<p>The set of papers includes results of a randomized, controlled, open label observational trial (<a href=\"https:\/\/www.iraqijms.net\/upload\/pdf\/iraqijms60db8b76d3b1e.pdf\">pdf<\/a>) that found ivermectin combined with\u00a0doxycycline, an antibiotic, reduced the time to recovery and the mortality rate, and a randomized, controlled, double-blinded <a href=\"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605211013550?url_ver=Z39.88-2003&#038;rfr_id=ori:rid:crossref.org&#038;rfr_dat=cr_pub%20%200pubmed\">trial<\/a> that found ivermectin and doxycycline quickened recovery and patients were less likely to see their disease progress.<\/p>\n<p>Of the 16 other studies, six reported\u00a0mixed results. For instance, Spanish researchers <a href=\"https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(20)30464-8\/fulltext\">reported in The Lancet<\/a> in February 2021 that ivermectin did not have an impact on testing results, but that there was \u201ca marked reduction\u201d of self-reported symptoms such as loss of smell and cough, and lower levels of viral loads. The result \u201cwarrants assessment in larger trials,\u201d the researchers said.<\/p>\n<p>The remaining 10 studies\u00a0returned results that did not favor ivermectin or did not achieve statistical significance.<\/p>\n<p>U.S. researchers, for example, found that ivermectin probably worked better than a placebo, but that the results did not achieve statistical significance, prompting them <a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2797483\">to say in October<\/a> that \u201cthis study adds to the growing evidence that there is not a clinically relevant treatment effect of ivermectin at this dose and duration.\u201d<\/p>\n<p>The FDA did not respond to a request for comment on the revelation that half of the studies it points to support using ivermectin (IVM) against COVID-19.<\/p>\n<p>Woodcock, the FDA\u2019s principal deputy commissioner, reviewed the studies. She was unimpressed.<\/p>\n<p>The Bangladeshi trial, for instance, was criticized for primarily including young persons, and having a higher number of dropouts in the placebo arm. Woodcock said the Israeli study did not report \u201cclinical outcomes\u201d and noted many of the other papers had small numbers of participants.<\/p>\n<p>\u201cThere are only a couple studies here that really look at the effects of IVM and see a positive clinical effect and they are much smaller than the negative studies,\u201d Woodcock told The Epoch Times in an email.<\/p>\n<p>The trials in favor of ivermectin are on the smaller side, and more likely to be observational. But that doesn\u2019t necessarily mean they are inferior, Kory said. He cited research <a href=\"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.MR000034.pub2\/full\">that found<\/a> there was little difference between observational studies and randomized-controlled trials, as well as a paper\u00a0<a href=\"https:\/\/www.atsjournals.org\/doi\/10.1164\/rccm.202010-3943ST\">that said<\/a> \u201cstudy design is only one factor that determines study quality.\u201d<\/p>\n<p>The FDA isn\u2019t the only government group opposed to using ivermectin to treat COVID-19. The National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel\u00a0<a href=\"https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/miscellaneous-drugs\/ivermectin\/\">recommends against<\/a>\u00a0it, citing several\u00a0of the larger trials that found little or no benefit for ivermectin. The panel cites none of the papers that found a positive effect.<\/p>\n<figure id=\"attachment_3985245\" class=\"wp-caption alignnone\"><a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-content\/uploads\/2022\/12\/ivermectin-1200x800-1.jpg\" rel=\"attachment wp-att-3985245\"><img loading=\"lazy\" decoding=\"async\" class=\"lazy size-large wp-image-3985245\" src=\"https:\/\/www.theepochtimes.com\/assets\/themes\/eet\/images\/white.png\" data-src=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-content\/uploads\/2022\/12\/ivermectin-1200x800-1.jpg\" alt=\"Epoch Times Photo\" width=\"640\" height=\"427\" \/><figcaption class=\"wp-caption-text\"><noscript><img loading=\"lazy\" decoding=\"async\" class=\"size-large wp-image-3985245\" src=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-content\/uploads\/2022\/12\/ivermectin-1200x800-1.jpg\" alt=\"Epoch Times Photo\" width=\"640\" height=\"427\" \/><\/noscript><\/figcaption><\/a> A health care worker holds a bottle of ivermectin in Colombia on July 21, 2020. (Luis Robayo\/AFP via Getty Images)<\/figure>\n<h2>Criticism of Design<\/h2>\n<p>Many of those studies have been criticized over their design. One major factor, critics say, is participants not receiving ivermectin soon after a positive test or the start of symptoms.<\/p>\n<p>In one trial, researchers <a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2797483\">acknowledged<\/a> that more than 4 out of 10 participants did not receive the dosage level that was listed as the \u201cgoal dose.\u201d Further, the median time from the start of symptoms to treatment was six days, and the treatment duration was just three days. The trial,\u00a0called ACTIV-6, was backed by the NIH.<\/p>\n<p>The corresponding author for the trial did not return a request for comment. The authors said that \u201cthere was no evidence of a differential treatment effect based on the median time of symptom onset to receipt of study drug.\u201d<\/p>\n<p>In another trial that <a href=\"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06348-5\">reported<\/a> little difference between the treatment and control groups, the treatment group received ivermectin days after starting to show symptoms.<\/p>\n<p>Ivermectin works best when applied within 24 hours of symptom manifestation, according to <a href=\"https:\/\/c19ivm.org\/meta.html\">a meta regression<\/a> of ivermectin studies performed by by an unnamed group of researchers.<\/p>\n<p>\u201cThey literally try to treat as late into the disease as they can, for a short duration as they can, at the lowest dose that they can. And they also try to find as healthy and mild patients as you can,\u201d Kory said.<\/p>\n<p>\u201cAnd yet, when they conduct those kinds of trials, it\u2019s on the front page of a high-impact journal and the conclusion states, \u2018this shows there\u2019s no role for ivermectin in treatments.\u2019 Absolutely absurd. And so it\u2019s it\u2019s really just corruption of these trials.\u201d<\/p>\n<div class=\"author_wrapper\">\n<div class=\"one_author_block round\">\n<div class=\"top_row\">\n\t\t\t\t\t<a href=\"https:\/\/www.theepochtimes.com\/author-zachary-stieber\"><img decoding=\"async\" src=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-content\/uploads\/2022\/10\/WEB_ZacharyStieber-1.jpg\" alt=\"Zachary Stieber\" \/><\/a><\/p>\n<p>Follow<\/p>\n<\/div>\n<p>Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news.<\/p>\n<\/p><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) says a drug called ivermectin does not work against COVID-19 but links to studies that show it does, an Epoch Times review has<\/p>\n","protected":false},"author":1,"featured_media":1767266,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[547],"tags":[5458,3774,7118,8468,8467,3819,4039],"class_list":["post-1773490","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-the-bongino-report","tag-bongino","tag-covid-19","tag-doesnt","tag-fda","tag-ivermectin","tag-report","tag-studies"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/1773490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=1773490"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/1773490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/1767266"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=1773490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=1773490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=1773490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}